These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 14742789

  • 1. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
    Shukla UA, Chi EM, Lehr KH.
    Ann Pharmacother; 2004 Jan; 38(1):30-5. PubMed ID: 14742789
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B.
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA, Ducharme MP, Edwards DJ, Slaughter RL, Grunberger G.
    Pharmacotherapy; 1996 Sep; 16(5):760-8. PubMed ID: 8888072
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 6. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 7. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H, Brickl R, Eschey H, Greischel A, Heinzel G, König E, Limmer J, Rupprecht E.
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [Abstract] [Full Text] [Related]

  • 8. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D.
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
    González-Ortiz M, Martínez-Abundis E, Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones.
    Rev Invest Clin; 2004 Aug; 56(3):327-33. PubMed ID: 15612515
    [Abstract] [Full Text] [Related]

  • 11. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S, Kidron M, Wohlgelernter J, Raz I.
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [Abstract] [Full Text] [Related]

  • 12. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 13. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
    Smulders RA, Zhang W, Veltkamp SA, van Dijk J, Krauwinkel WJ, Keirns J, Kadokura T.
    Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
    [Abstract] [Full Text] [Related]

  • 14. [Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
    Tang JZ, Mao JP, Yang ZF, Zhou ZG, Tang WL, Feng Q.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):631-4. PubMed ID: 16114544
    [Abstract] [Full Text] [Related]

  • 15. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS, Aslam M, Naveed AK, Razi MS.
    Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
    [Abstract] [Full Text] [Related]

  • 16. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT.
    Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
    Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V.
    Diabetologia; 1996 Dec; 39(12):1617-24. PubMed ID: 8960852
    [Abstract] [Full Text] [Related]

  • 18. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R.
    Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
    [Abstract] [Full Text] [Related]

  • 20. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA, Bergman A, Yi B, Kipnes M, Sitagliptin Study 012 Group.
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.